Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kirk Barnes"'
Autor:
Michel E. Kuzur, Dianna Shipley, Mathew John Joseph, Laura Blakely, Cassie M. Lane, Mark Mainwaring, Chris Earwood, Johanna C. Bendell, Chandra Reddy, Ronald Blachly, Kirk Barnes
Publikováno v:
Cancer investigation. 35(6)
This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. Patients with mCRC received mFOLFOX/bevacizumab followed by axi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692c20fb281726eabcbbe4498488e614
https://pubmed.ncbi.nlm.nih.gov/28426267
https://pubmed.ncbi.nlm.nih.gov/28426267
Autor:
Howard A. Burris, Edward Arrowsmith, E. Kirk Barnes, Michael McCleod, David R. Spigel, Johanna C. Bendell, Jeffrey R. Infante, John D. Hainsworth, F. Anthony Greco, Dianna Shipley
Publikováno v:
Clinical Colorectal Cancer. 11:45-52
Background and Purpose We wanted to evaluate the efficacy, defined as 2-year disease-free survival (DFS), and safety of bevacizumab/chemoradiation in preoperative and adjuvant settings for patients with stage II/III rectal cancer. Patients and Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7967c3863c7864f1cd4d88dc2c27812b
https://doi.org/10.1016/j.clcc.2011.04.002
https://doi.org/10.1016/j.clcc.2011.04.002
Publikováno v:
Journal of Clinical Oncology. 33:e14673-e14673
e14673 Background: Maintenance therapy is commonly used in the first-line treatment of mCRC. Maintenance therapy options include fluorouracil plus bev and bev single agent. Ax is an oral, potent, a...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b5dc9db189d6f1c940c961d4532af02
https://doi.org/10.1200/jco.2015.33.15_suppl.e14673
https://doi.org/10.1200/jco.2015.33.15_suppl.e14673